ArticleEClinicalMedicine2026
Celiac plexus radiosurgery for retroperitoneal pain in advanced cancer: a pre-specified secondary analysis of health-related quality of life in a phase II single-arm trial.
Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03323489 (Celiac Plexus Radio-Surgery for Pain Management in Advanced Cancer Patients - a Phase II Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Celiac Plexus Radio-Surgery for Pain Management in Advanced Cancer Patients - a Phase II Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retroperitoneal pain syndrome seen in pancreatic cancer is a major clinical challenge. Celiac plexus radiosurgery, a new palliative technique for retroperitoneal pain syndrome, decreased pain levels in a phase II study. Here Health-Related Quality of Life (HRQOL) outcomes are reported. Methods: Evaluable patients, who were enrolled between January 2018 and December 2021, in an international single-arm Phase II ethics-approved study (NCT03323489), were included. The pre-specified secondary endpoint-change in HRQOL from baseline to 3- and 6-weeks post-treatment, was measured by the Functional Assessment of Cancer Therapy - Hepatobiliary (FACT-Hep) version 4 questionnaire. Mean change was deemed clinically significant (CS) if the lower bound of the 95% confidence interval was above the predefined minimal clinically important difference (MCID) for that outcome. Findings: Of 90 evaluable patients, 51 (57%) and 44 (49%) had HRQOL FACT-Hep scores available at 3- and 6-weeks, compared to baseline. The majority of patients had pancreatic cancer (90%) and mean daily intravenous morphine equivalent consumption was 35.9 mg (SD 67.6).The mean increase of FACT-Hep total score from baseline was 9.3 points at 3-weeks (p = 0.0017) and 19.6 points at 6-weeks (p < 0.0001, 95% CI 13-26.3), representing a statistically significant (SS) 22% improvement from baseline, with CS demonstrated at 6-weeks. A sensitivity analysis, imputing no change from baseline in patients with missing data, demonstrated similar results. On multivariable analysis, lower baseline opioid use and baseline FACT-Hep scores were associated with an increased change in FACT-Hep from baseline to 3-weeks. Interpretation: Celiac plexus radiosurgery was associated with a SS improvement in HRQOL amongst patients with retroperitoneal pain at 3-weeks, and a SS and CS improvement at 6-weeks post intervention. Funding: This study received major financial support provided by Gateway for Cancer Research (G-17-100), additional support was provided from the Israel Cancer Association (20170128 and 20181272).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.